Mimedx (MDXG) Assets (2010 - 2026)
Mimedx recorded quarterly Assets of $308.7 million in Q1 2026, down 9.92% quarter-over-quarter from $342.7 million in Q4 2025, and up 14.15% year-over-year from $270.4 million in Q1 2025.
Mimedx's Assets history runs 17 years deep, the most recent figure standing at $308.7 million for Q1 2026.
- In Q1 2026, Assets rose 14.15% year-over-year to $308.7 million; the TTM figure through Mar 2026 stood at $308.7 million (up 14.15% YoY), while the FY2025 annual figure was $342.7 million, up 29.83% from the prior year.
- Assets came in at $308.7 million for Q1 2026 at Mimedx, down from $342.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $342.7 million in Q4 2025 to a low of $168.2 million in Q1 2023.
- A 5-year average of $232.4 million and a median of $230.2 million in 2024 frame the typical range for Assets.
- Across the five-year window, Assets dropped 9.87% in 2022 and surged 39.44% in 2023, its largest moves.
- Mimedx's Assets stood at $171.4 million in 2022, then surged by 39.44% to $239.0 million in 2023, then advanced by 10.4% to $263.9 million in 2024, then increased by 29.83% to $342.7 million in 2025, then fell by 9.92% to $308.7 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $308.7 million, $342.7 million, and $319.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 308.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 308.68 Mn |
| Dec 31, 2025 | 342.65 Mn |
| Sep 30, 2025 | 318.99 Mn |
| Jun 30, 2025 | 291.11 Mn |
| Mar 31, 2025 | 270.42 Mn |
| Dec 31, 2024 | 263.92 Mn |
| Sep 30, 2024 | 243.89 Mn |
| Jun 30, 2024 | 230.18 Mn |
| Mar 31, 2024 | 221.68 Mn |
| Dec 31, 2023 | 239.05 Mn |
| Sep 30, 2023 | 189.02 Mn |
| Jun 30, 2023 | 176.38 Mn |
| Mar 31, 2023 | 168.16 Mn |
| Dec 31, 2022 | 171.43 Mn |
| Sep 30, 2022 | 172.80 Mn |
| Jun 30, 2022 | 168.67 Mn |
| Mar 31, 2022 | 174.44 Mn |
| Dec 31, 2021 | 187.93 Mn |
| Sep 30, 2021 | 180.52 Mn |
| Jun 30, 2021 | 187.15 Mn |
| Mar 31, 2021 | 190.81 Mn |
| Dec 31, 2020 | 202.03 Mn |
| Sep 30, 2020 | 213.32 Mn |
| Jun 30, 2020 | 150.91 Mn |
| Mar 31, 2020 | 158.91 Mn |
| Dec 31, 2019 | 167.17 Mn |
| Sep 30, 2019 | 179.27 Mn |
| Jun 30, 2019 | 170.31 Mn |
| Mar 31, 2019 | 107.44 Mn |
| Dec 31, 2018 | 122.84 Mn |
| Dec 31, 2017 | 121.26 Mn |
| Sep 30, 2017 | 178.71 Mn |
| Jun 30, 2017 | 199.87 Mn |
| Mar 31, 2017 | 188.49 Mn |
| Dec 31, 2016 | 117.27 Mn |
| Sep 30, 2016 | 181.67 Mn |
| Jun 30, 2016 | 177.06 Mn |
| Mar 31, 2016 | 177.22 Mn |
| Dec 31, 2015 | 135.91 Mn |
| Sep 30, 2015 | 125.93 Mn |
| Jun 30, 2015 | 113.84 Mn |
| Mar 31, 2015 | 106.11 Mn |
| Dec 31, 2014 | 109.26 Mn |
| Sep 30, 2014 | 97.32 Mn |
| Jun 30, 2014 | 86.02 Mn |
| Mar 31, 2014 | 87.35 Mn |
| Dec 31, 2013 | 84.69 Mn |
| Sep 30, 2013 | 45.30 Mn |
| Jun 30, 2013 | 40.28 Mn |
| Mar 31, 2013 | 37.85 Mn |
| Dec 31, 2012 | 35.18 Mn |
| Sep 30, 2012 | 33.54 Mn |
| Jun 30, 2012 | 27.47 Mn |
| Mar 31, 2012 | 26.86 Mn |
| Dec 31, 2011 | 27.10 Mn |
| Sep 30, 2011 | 23.55 Mn |
| Jun 30, 2011 | 24.28 Mn |
| Dec 31, 2010 | 7.35 Mn |